Myokardia Inc (NASDAQ:MYOK) Insider Sells $852,942.48 in Stock

Myokardia Inc (NASDAQ:MYOK) insider Jake Bauer sold 13,096 shares of the stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $65.13, for a total value of $852,942.48. Following the completion of the sale, the insider now owns 53,134 shares of the company’s stock, valued at approximately $3,460,617.42. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Jake Bauer also recently made the following trade(s):

  • On Friday, November 29th, Jake Bauer sold 21,232 shares of Myokardia stock. The stock was sold at an average price of $65.17, for a total value of $1,383,689.44.
  • On Friday, September 20th, Jake Bauer sold 19,700 shares of Myokardia stock. The stock was sold at an average price of $60.09, for a total value of $1,183,773.00.

Shares of NASDAQ:MYOK traded up $0.02 during trading on Monday, hitting $65.17. The stock had a trading volume of 663,645 shares, compared to its average volume of 425,082. Myokardia Inc has a 12 month low of $39.01 and a 12 month high of $66.44. The company has a market capitalization of $3.01 billion, a PE ratio of -37.03 and a beta of 2.07. The firm’s fifty day moving average is $57.77 and its 200 day moving average is $53.07.

Myokardia (NASDAQ:MYOK) last announced its earnings results on Monday, November 11th. The biotechnology company reported ($1.34) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.91) by $0.57. As a group, equities analysts expect that Myokardia Inc will post -4.6 earnings per share for the current fiscal year.

Large investors have recently made changes to their positions in the company. Quadrant Capital Group LLC bought a new position in shares of Myokardia in the 3rd quarter worth approximately $33,000. Amundi Pioneer Asset Management Inc. bought a new position in shares of Myokardia in the 1st quarter worth approximately $68,000. Aperio Group LLC bought a new position in shares of Myokardia in the 2nd quarter worth approximately $92,000. Strs Ohio raised its position in shares of Myokardia by 440.0% in the 3rd quarter. Strs Ohio now owns 2,700 shares of the biotechnology company’s stock worth $140,000 after acquiring an additional 2,200 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Myokardia by 39.3% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,803 shares of the biotechnology company’s stock worth $141,000 after acquiring an additional 791 shares in the last quarter.

Several research firms have weighed in on MYOK. Zacks Investment Research upgraded Myokardia from a “sell” rating to a “hold” rating in a report on Tuesday, August 13th. ValuEngine upgraded Myokardia from a “buy” rating to a “strong-buy” rating in a report on Friday, November 1st. Maxim Group reiterated an “average” rating on shares of Myokardia in a report on Monday, October 28th. BidaskClub upgraded Myokardia from a “hold” rating to a “buy” rating in a report on Saturday. Finally, Guggenheim initiated coverage on Myokardia in a report on Thursday, September 19th. They issued a “buy” rating for the company. Two equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $76.89.

About Myokardia

MyoKardia, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. Its lead product candidate is mavacamten, an orally administered small molecule, which is in Phase III clinical trial that is designed to reduce left ventricular contractility to alleviate the functional consequences and symptoms of obstructive hypertrophic cardiomyopathy (HCM) and prevent or reverse HCM progression, as well as in Phase II clinical trial for non-obstructive HCM.

Further Reading: What is the Ex-Dividend Date in Investing?

Insider Buying and Selling by Quarter for Myokardia (NASDAQ:MYOK)

Receive News & Ratings for Myokardia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myokardia and related companies with MarketBeat.com's FREE daily email newsletter.